Peter Radovich Sells 1,998 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36. Following the completion of the transaction, the chief operating officer now directly owns 27,015 shares of the company’s stock, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $42.00 on Friday. The company’s 50-day moving average is $42.93 and its 200-day moving average is $40.62. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market capitalization of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the business posted ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% compared to the same quarter last year. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC increased its position in Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank increased its position in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after acquiring an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares during the period. ProShare Advisors LLC acquired a new stake in Mirum Pharmaceuticals in the 2nd quarter worth about $213,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $215,000.

Analysts Set New Price Targets

MIRM has been the subject of several analyst reports. Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.